Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072135 · ClinicalTrials.gov registry record · NA
Exparel and Ankle Surgery
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02072135 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 4 participants.
The verdict
NCT02072135, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study involves a drug called Exparel that has been approved by the US Food and Drug Administration (FDA), for application directly to wound sites. EXPAREL® is a long acting pain reliever. It is being given in this study to see if it provides safe and effective pain relief after ankle surgery. Because it is a long acting drug, it may lessen pain relief for as much as 72 hours after surgery. EXPAREL® has not been approved by the FDA for administration by popliteal block, which is the method the study doctors will use to give the patients the drug. Giving the drug by popliteal block involves inserting a small tube in to the back of the knee to deliver the drug. The study doctors wish to determine if patients undergoing ankle surgery and receiving this drug have less pain and less need for narcotic medication.
Interventions
- DRUG Exparel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072135
The ClinicalTrials.gov registry entry for NCT02072135 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exparel is the first listed.
NCT02072135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072135 about?
NCT02072135 is a clinical study titled "Exparel and Ankle Surgery". This study involves a drug called Exparel that has been approved by the US Food and Drug Administration (FDA), for application directly to wound sites. EXPAREL® is a long acting pain reliever. It is being given in this study to see if it provides safe and effective pain relief after ankle surgery. B...
What is the current status of trial NCT02072135?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2014-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02072135?
The interventions under investigation include: Exparel (DRUG).
Who is sponsoring clinical trial NCT02072135?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.